Renaissance Technologies LLC grew its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 65.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 114,654 shares of the company's stock after purchasing an additional 45,200 shares during the period. Renaissance Technologies LLC owned about 0.20% of Ginkgo Bioworks worth $1,126,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. FNY Investment Advisers LLC boosted its position in Ginkgo Bioworks by 125.6% in the fourth quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company's stock valued at $745,000 after buying an additional 42,298 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $199,000. KBC Group NV acquired a new stake in shares of Ginkgo Bioworks during the 4th quarter valued at $31,000. Forbes J M & Co. LLP grew its position in Ginkgo Bioworks by 461.4% during the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after acquiring an additional 576,732 shares during the last quarter. Finally, Palumbo Wealth Management LLC acquired a new position in Ginkgo Bioworks in the 4th quarter worth about $144,000. 78.63% of the stock is owned by institutional investors.
Ginkgo Bioworks Trading Down 8.1 %
Ginkgo Bioworks stock opened at $7.37 on Wednesday. The company has a market capitalization of $427.71 million, a PE ratio of -0.56 and a beta of 1.34. The stock has a 50-day moving average price of $7.45 and a two-hundred day moving average price of $9.15. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $41.20.
About Ginkgo Bioworks
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
